Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-30 pm EST
9.280 USD   +1.09%
01/10Transcript : ALX Oncology Holdings Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 10:30 AM
CI
01/09Alx Oncology : Corporate Presentation
PU
01/05ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ALX Oncology to Present New Clinical Data on Evorpacept ináAcute Myeloid Leukemia at 64th ASH Annual Meeting

11/03/2022 | 08:01am EST

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the Company will be presenting clinical data from the dose escalation portion of ASPEN-05, a Phase 1 study evaluating evorpacept in combination with azacitidine and venetoclax for the treatment of acute myeloid leukemia (“AML”) at the 64th American Society of Hematology (“ASH”) Annual Meeting held December 10-13, 2022 in New Orleans, Louisiana.

The accepted abstract is listed below and is now available online on the ASH website: http://www.hematology.org/Annual-Meeting/Abstracts/.

Poster Presentation Details

Title: Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part

Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III

Presentation Date and Location: Monday, December 12, 2022, 6:00pm – 8:00pm CT, Ernest N. Morial Convention Center, Hall D

Publication Number: 4076
    

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.


All news about ALX ONCOLOGY HOLDINGS INC.
01/10Transcript : ALX Oncology Holdings Inc. Presents at 41st Annual J.P. Morgan H..
CI
01/09Alx Oncology : Corporate Presentation
PU
01/05ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023
GL
01/03ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
GL
01/03ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
AQ
2022Alx Oncology : ASH 2022 Conference Call Presentation
PU
2022Transcript : ALX Oncology Holdings Inc. - Special Call
CI
2022ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination wi..
GL
2022Alx Oncology Announces Initial Data from Aspen-05 Study of Evorpacept in Combination wi..
CI
2022ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination wi..
GL
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -131 M - -
Net cash 2022 255 M - -
P/E ratio 2022 -2,91x
Yield 2022 -
Capitalization 378 M 378 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 55
Free-Float 73,6%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 9,28 $
Average target price 35,00 $
Spread / Average Target 277%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. GarcÝa Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-18.54%374
VERTEX PHARMACEUTICALS11.31%82 513
REGENERON PHARMACEUTICALS, INC.2.96%79 336
WUXI APPTEC CO., LTD.18.94%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008